Synovis Life Technologies, Inc. (Nasdaq: SYNO)

Synovis Life Technologies, Inc. (Nasdaq: SYNO) announced that it would be acquired by Baxter (NYSE: BAX) for $28 per share cash, in a $325 million deal. Synovis is a leading provider of biological and mechanical products for soft tissue repair used in a variety of surgical procedures. The acquisition complements and will expand the portfolio of Baxter's regenerative medicine and biosurgery franchise, which includes a number of devices and biological products for hemostasis, tissue sealing and adherence. Synovis was included on Deloitte's 2011 Technology Fast 500(TM) list, which ranks the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. In August the Company announced a 19% increase in net revenue year-over-year, and CEO Richard Kramp said, "For the 17th consecutive quarter, in a challenging healthcare economic climate, we have posted double-digit sales gains and established a firm foundation for continued growth."

If you are a current shareholder and would like to discuss your options of exercising your rights as a shareholder, which include ensuring that the company is getting the highest possible price for the company, and that the board of directors will act in the best interest of the shareholders, please contact us.

Please submit the following information so we can determine if you qualify for the suit. If you don't know all the specific details, partial information is also acceptable.

Personal Information
Name:
Phone #:
E-mail Address:
Stock Information
Do you currently own the stock? Yes   No
Purchase Date:
Quantity Purchased:
Purchase Price Per Share: